Santoro F, Núñez-Gil IJ, Viana-Llamas MC, et al. - For coronavirus disease 2019, currently there is no recommended standard therapy, including anticoagulation regimens. Researchers herein examined the efficacy of anticoagulation in coronavirus disease 2019 hospitalized patients and determined how it influences survival. From multicenter international prospective registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019), data of 5,838 consecutive coronavirus disease 2019 patients were assessed. Of these patients, 5,480 (94%) were not provided any anticoagulation before hospitalization. Anticoagulation therapy was provided to 2,601 (44%) during hospitalization; it was not linked with better survival rate (81% vs 81%) but with higher risk of bleeding (2.7% vs 1.8%). Overall findings suggest that in the general population with coronavirus disease 2019, there was no correlation of anticoagulation therapy with better survival rates but with higher bleeding risk. Patients admitted with respiratory failure and requiring invasive ventilation had better results.